Krystal Biotech (KRYS) Cash from Investing Activities (2016 - 2026)

Krystal Biotech has reported Cash from Investing Activities for 11 years, with the latest figure at -$161.6 million in Q2 2026.

• Cash from Investing Activities for Q2 2026 came in at -$161.6 million, down 1435.24% year-over-year; the trailing twelve-month figure through Jun 2026 was -$218.3 million (down 19.02% YoY), and the FY2025 annual result was -$58.4 million, up 64.26% from the prior year.
• Cash from Investing Activities slipped to -$161.6 million in Q2 2026, from -$63.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $105.2 million in Q3 2023 and troughed at -$161.6 million in Q2 2026.
• A 5-year average of -$26.6 million and a median of -$17.7 million in 2023 frame the typical range for Cash from Investing Activities.
• The widest annual swing landed in 2022, when Cash from Investing Activities plunged 7384.34%; it then surged 813.5% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$5.2 million in 2022, then slumped by 95.08% to -$10.2 million in 2023, then tumbled by 724.59% to -$83.8 million in 2024, then soared by 113.32% to $11.2 million in 2025, then plunged by 1547.5% to -$161.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$161.6 million in Q2 2026, -$63.6 million in Q1 2026, and $11.2 million in Q4 2025.